Is MUC1 A Viable Therapeutic Target For Patients With The Asbestos-induced Tumour Malignant Mesothelioma?
Funder
National Health and Medical Research Council
Funding Amount
$465,068.00
Summary
The deadly asbestos-induced cancer mesothelioma is continuing to kill tens of thousands of people each year. Most patients are diagnosed with advanced disease. We are investigating the use of a specific marker, called MUC1, to improve mesothelioma diagnosis. Improved diagnosis will reduce the time taken to commence treatment. It will also reduce hospital costs and the number of surgical procedures a patients must undergo.
This project will update the Wittenoom cohorts by tracing cancers and deaths in Australia and Italy. This will improve risk estimates of lung cancer and mesothelioma. In particular we will see if that risk declines with more than 40 years since exposure, in collaboration with Italian colleagues. We will continue developing an interactive community website to act as a support platform, a layman's bridge to medical research knowledge, public health information and an archive of personal stories.